Drugs That Distort eGFR: Medications That Falsify Your Kidney Function Test

What eGFR Actually Measures

Estimated glomerular filtration rate (eGFR) is a calculation, not a direct measurement. Laboratories plug your serum creatinine concentration, age, and sex into the CKD-EPI 2021 equation to estimate the volume of plasma your kidneys filter per minute. The result is reported in mL/min/1.73 m².

Why creatinine is the weak link

Creatinine is a byproduct of muscle metabolism that the kidneys both filter at the glomerulus and secrete through the proximal tubule. Any drug that blocks tubular secretion will raise serum creatinine even though the glomerulus is filtering at the same rate. The CKD-EPI equation cannot distinguish between a true GFR decline and a secretion block [1].

The 2021 equation update

In 2021, the National Kidney Foundation and the American Society of Nephrology recommended removing the race coefficient from the CKD-EPI formula [1]. The updated equation reclassified roughly 17.3% of Black adults previously categorized at a higher GFR into lower eGFR stages, changing medication eligibility decisions for drugs with renal cutoffs [2]. This makes drug-induced creatinine artifacts even more consequential, because the margin between "continue" and "hold" has narrowed.

Drugs That Falsely Lower eGFR

These medications raise serum creatinine by inhibiting its tubular secretion or interfering with the creatinine assay. Actual glomerular filtration remains intact.

Trimethoprim (Bactrim, Septra)

Trimethoprim blocks the organic cation transporter OCT2 in the proximal tubule, reducing creatinine secretion by 20 to 40% [3]. A patient on trimethoprim-sulfamethoxazole for a urinary tract infection can see serum creatinine jump 0.3 to 0.5 mg/dL within 48 hours. The eGFR drop is entirely artifactual. "Clinicians should not discontinue renally dosed medications based on a creatinine rise during trimethoprim therapy without confirming the finding with cystatin C or a measured GFR," per KDIGO 2024 commentary on drug-creatinine interference [4].

Cobicistat and ritonavir

Cobicistat, the pharmacokinetic booster in HIV regimens like Genvoya and Stribild, inhibits the MATE1 transporter and raises serum creatinine by approximately 0.1 to 0.15 mg/dL within two to four weeks of initiation [5]. Ritonavir produces a smaller but measurable effect through the same mechanism. The FDA prescribing information for cobicistat specifically notes that this creatinine increase does not reflect a change in actual GFR and recommends establishing a new baseline after four weeks.

Cimetidine

Cimetidine, the older H2-receptor antagonist, inhibits tubular creatinine secretion at therapeutic doses. A 400 mg twice-daily regimen can raise serum creatinine by 0.2 to 0.4 mg/dL [6]. Famotidine and ranitidine do not produce this effect to a clinically meaningful degree.

Drospirenone

The progestin drospirenone (found in Yaz, Yasmin, Slynd) has mild antimineralocorticoid activity and can raise serum creatinine by 0.05 to 0.1 mg/dL [7]. In a young woman with baseline creatinine of 0.6 mg/dL, that shift could reclassify her eGFR downward by 10 to 15 mL/min/1.73 m². The effect reverses within one cycle of discontinuation.

Creatine supplements

Exogenous creatine (monohydrate, HCl) is metabolized to creatinine. Individuals taking 5 to 10 g daily can raise serum creatinine by 0.3 to 0.8 mg/dL, producing eGFR values that mimic Stage 2 or Stage 3a CKD in otherwise healthy adults [8]. This is the single most common non-prescription cause of falsely low eGFR in the telehealth population taking peptides or performance supplements.

Drugs That Alter True GFR Through Hemodynamic Effects

Unlike the secretion inhibitors above, these medications genuinely change the rate of glomerular filtration, but the change is reversible, expected, and often protective.

ACE inhibitors and ARBs

Lisinopril, losartan, valsartan, and their class peers dilate the efferent arteriole, reducing intraglomerular pressure. EGFR may drop 10 to 25% in the first one to two weeks [9]. The KDIGO 2024 guidelines recommend tolerating up to a 30% eGFR decline after RAAS inhibitor initiation without stopping the drug, because the long-term nephroprotective benefit outweighs the acute hemodynamic dip.

SGLT2 inhibitors

Empagliflozin, dapagliflozin, and canagliflozin produce a characteristic "eGFR dip" of 3 to 5 mL/min/1.73 m² in the first two weeks due to tubuloglomerular feedback activation [10]. In EMPA-REG OUTCOME (N=7,020), empagliflozin's initial eGFR decline reversed by week 4, and the empagliflozin group had a significantly slower long-term eGFR slope compared to placebo (0.19 vs. 1.67 mL/min/1.73 m² per year) [10]. The CREDENCE trial (N=4,401) confirmed this pattern with canagliflozin, showing a 30% lower risk of the composite kidney endpoint [11].

NSAIDs

Ibuprofen, naproxen, and celecoxib inhibit prostaglandin-mediated afferent arteriolar dilation. In volume-depleted patients or those on concurrent RAAS inhibitors, NSAIDs can reduce true GFR by 20 to 50% [12]. Unlike ACE/ARB-related dips, NSAID-induced GFR reductions carry real risk of acute kidney injury if sustained, per the AHA scientific statement on NSAID cardiovascular and renal risk.

Diuretics

Loop diuretics (furosemide, bumetanide) and thiazides reduce effective circulating volume, which lowers GFR in a dose-dependent fashion. A patient started on furosemide 40 mg daily may show a 5 to 15% eGFR decline within the first week [13]. This is a true filtration change, but it is prerenal and reversible with volume repletion.

Why eGFR Artifacts Matter for Medication Dosing

Renal dosing thresholds are binary cutoffs. A falsely low eGFR can push a patient across a threshold and trigger inappropriate drug modifications.

Metformin

The FDA revised metformin labeling uses eGFR cutoffs: initiation is contraindicated below 30 mL/min/1.73 m², and the dose should be reassessed between 30 and 45 mL/min/1.73 m². A patient on trimethoprim whose true eGFR is 48 but whose lab reads 35 could have metformin dose-reduced or held unnecessarily, worsening glycemic control [14].

GLP-1 receptor agonists

Semaglutide (Ozempic, Wegovy) has no specific eGFR cutoff for dose adjustment, but liraglutide and dulaglutide carry warnings about monitoring in eGFR <30 populations [15]. The FLOW trial (N=3,533) demonstrated that semaglutide 1.0 mg weekly reduced the risk of major kidney events by 24% in patients with type 2 diabetes and CKD (eGFR 25 to 75 mL/min/1.73 m²) [15]. A falsely low eGFR might inappropriately flag a patient as "advanced CKD" and delay GLP-1 initiation that would have been renoprotective.

Dapagliflozin

DAPA-CKD (N=4,304) enrolled patients with eGFR 25 to 75 mL/min/1.73 m² and showed a 39% reduction in the composite kidney endpoint [16]. The FDA approved dapagliflozin for CKD down to eGFR 25. But prescribers unfamiliar with the initial eGFR dip may mistake it for progression and stop the drug within the first month.

DOACs

Apixaban and rivaroxaban have renal dose adjustments at eGFR 25 and 50, respectively. A 0.3 mg/dL creatinine artifact from trimethoprim could shift a patient from standard-dose to reduced-dose anticoagulation, increasing stroke risk [17].

How to Identify and Manage eGFR Artifacts

Step 1: Check the medication list

Before acting on an unexpected eGFR drop, review the patient's active prescriptions and supplements for creatinine-interfering agents. The table below groups the most common offenders.

| Drug / Supplement | Mechanism | Typical Creatinine Rise | Reversible? | |---|---|---|---| | Trimethoprim | OCT2 inhibition | 0.3 to 0.5 mg/dL | Yes, within 48 h of stopping | | Cobicistat | MATE1 inhibition | 0.1 to 0.15 mg/dL | Yes, within 1 to 2 weeks | | Cimetidine | Tubular secretion block | 0.2 to 0.4 mg/dL | Yes, within 3 days | | Drospirenone | Antimineralocorticoid | 0.05 to 0.1 mg/dL | Yes, within 1 cycle | | Creatine (5 to 10 g/d) | Increased creatinine production | 0.3 to 0.8 mg/dL | Yes, within 3 to 4 weeks | | Fenofibrate | Increased creatinine production | 0.1 to 0.2 mg/dL | Yes, within 1 to 2 weeks |

Step 2: Order cystatin C

Cystatin C is a 13-kDa protein produced by all nucleated cells at a constant rate. It is freely filtered by the glomerulus and not secreted by the tubules, so drugs that block creatinine secretion do not affect it [18]. The CKD-EPI cystatin C equation provides an eGFR estimate that is independent of muscle mass and creatinine-interfering medications. KDIGO recommends confirmatory cystatin C testing when creatinine-based eGFR is suspected to be inaccurate [4].

Step 3: Trend, do not react to a single value

A single eGFR measurement has a biological coefficient of variation of approximately 5 to 7% [19]. "An isolated creatinine value should never trigger a permanent medication change," noted Dr. Andrew Levey of Tufts Medical Center, co-developer of the CKD-EPI equation, in a 2021 editorial in the New England Journal of Medicine. Confirm any unexpected eGFR decline with a repeat test at 7 to 14 days, ideally with cystatin C.

Drugs That Can Falsely Raise eGFR

Fewer drugs artificially inflate eGFR, but they exist.

Corticosteroids

Chronic corticosteroid use increases muscle catabolism acutely, which can transiently raise creatinine. However, prolonged use with muscle wasting (sarcopenia) reduces creatinine production, causing eGFR to overestimate true kidney function [20]. A patient on prednisone 20 mg daily for six months who has lost 5 kg of lean mass may show an eGFR of 85 while their true GFR is closer to 65.

Severe malnutrition and muscle wasting

This is not a drug effect per se, but patients on GLP-1 agonists who lose significant lean mass during rapid weight loss may develop falsely elevated eGFR. In STEP-1 (N=1,961), participants on semaglutide 2.4 mg lost a mean of 14.9% total body weight at 68 weeks, with approximately 39% of that loss coming from lean mass [21]. The resulting reduction in creatinine production could mask early kidney disease.

Flucytosine assay interference

Flucytosine (5-FC), an antifungal, interferes with certain enzymatic creatinine assays (Jaffe method), producing falsely low creatinine and falsely high eGFR [22]. This is rare outside oncology and transplant settings but worth noting for completeness.

Special Populations: Telehealth and Peptide Users

Patients in the HealthRX population frequently take creatine, peptides like BPC-157 or TB-500, and performance supplements alongside prescribed medications. A 32-year-old male on TRT, creatine monohydrate 5 g daily, and trimethoprim for a skin infection could present with a creatinine of 1.8 mg/dL and an eGFR of 48 mL/min/1.73 m², suggesting Stage 3a CKD. Stopping creatine for three weeks and rechecking with cystatin C might reveal a true eGFR above 95.

Practical protocol for telehealth labs

1. Instruct patients to pause creatine supplements for at least 72 hours (ideally 3 weeks for full washout) before lab draws.
2. Flag active trimethoprim, cobicistat, or cimetidine prescriptions in the chart review before interpreting eGFR.
3. Order cystatin C alongside creatinine for any patient on two or more creatinine-interfering agents.
4. Do not adjust metformin, GLP-1, or SGLT2 inhibitor dosing based on a single eGFR reading obtained during concurrent use of a known interfering drug.

Normal eGFR Ranges and CKD Staging

For reference, KDIGO defines CKD stages by sustained eGFR levels [4]:

| CKD Stage | eGFR (mL/min/1.73 m²) | Description | |---|---|---| | G1 | ≥90 | Normal or high | | G2 | 60 to 89 | Mildly decreased | | G3a | 45 to 59 | Mildly to moderately decreased | | G3b | 30 to 44 | Moderately to severely decreased | | G4 | 15 to 29 | Severely decreased | | G5 | <15 | Kidney failure |

A diagnosis of CKD requires the eGFR abnormality (or albuminuria) to persist for at least 90 days [4]. A single low reading during trimethoprim therapy does not meet this definition.